Abstract
Objective To compare the efficary between posterior subtenon injection of triamcinolone acetonide(TA)and intravitreal injection of ranibizumab for the treatment of non-artertic anterior ischemic optic neuropathy (NAION). Methods Total of 60 eyes of 60 patients who were diagnosed as NAION from Jun. 2016 to Jun. 2018 were randomly divided into two groups.Group A, 30 eyes of 30 patients, received poeterior subtenon injection of triamcinolone acetonide (TA, 20mg). Group B, 30 eyes of 30 cases, received intravitreal injection of ranibizumab. The visual acuity, visual field and optic disc edema were recorded after treatment. Results The visual acuity, visual field and optic disc edema at 15 days after treatment were improved.In group A the vision field improved in 14 eyes (93.33%)among 15 eyes who received visual field examination, unchannged in 1 eye (6.67%). In group B the vision field were improved in 12 eyes(83.33%)among 15 eyes who received visual field examination, and unchannged in 3 eyes(16.67%). Conclusion Triamcinolone acetonide (TA) has the same efficacy as ranibizumab in the treatment of NAION.Triamcinolone acetonide are superior to Ranibizumab in economics and safety. Key words: Neuropathy, optic, ischemic, anterior, non-arteritic; Triamcinolone acetonide, subtenon injection; Ranibizumab, intravitreal injection
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
